Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology. The study is enrolling in 6 comprehensive cancer centers in the US.
- 20 Sep 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Jul 2020.
- 20 Sep 2018 Status changed from not yet recruiting to recruiting.